Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
| Data(s) |
2011
|
|---|---|
| Identificador |
http://serval.unil.ch/?id=serval:BIB_15E65DE45ADE isbn:1474-5488 (Electronic) pmid:21111679 doi:10.1016/S1470-2045(10)70258-8 isiid:000286362100008 |
| Idioma(s) |
en |
| Fonte |
Lancet Oncology, vol. 12, no. 1, pp. 9-11 |
| Palavras-Chave | #Antineoplastic Agents/blood; Drug Industry; Drug Monitoring; Humans; Neoplasms/drug therapy; Neoplasms/metabolism; Piperazines/blood; Protein Kinase Inhibitors/blood; Pyrimidines/blood |
| Tipo |
info:eu-repo/semantics/article article |
